Table 1.

Clinical characteristics of enrolled FL patients (n = 261)

Characteristic	Datum	Percentage
Age, median (range), y	58.1 (19.7-90.5)
Male:female ratio	135:126
Stage at diagnosis
I/II/III/IV	70/24/47/120	26.8/9.2/18.0/45.9
FLIPI
Low/intermediate/high/missing data	127/61/70/3	49.2/23.6/27.1*
FLIPI-2
Low/intermediate/high/missing data	20/34/25/182	25.3/43.0/31.6*
Grade
1,2/3A/unknown	197/54/10	78.5/21.5*
Treatment
Rituximab-CHOP	89	34.1
Radiation	61	23.4
Rituximab-bendamustine	29	11.1
Observation	21	8.0
Rituximab	16	6.1
Rituximab-CVP	13	4.6
Radiation, R-CHOP	4	1.5
Radiation, rituximab	2	0.8
CHOP	2	0.8
Rituximab-EPOCH	2	0.8
Biaxin/chlorambucil	1/1	0.4/0.4
Rituximab-CHEP/rituximab-CDOP/rituximab-GCVP/DA-EPOCH-rituximab	1/1/1/1	0.4/0.4/0.4/0.4
Rituximab, IFN a/rituximab, fludarabine/rituximab, Cytoxan,† prednisone/rituximab, fludarabine, mitoxantrone, Decadron†/methotrexate	1/1/1/1/1	0.4/0.4/0.4/0.4/0.4
Lost follow-up	11	4.2
Interval between initial biopsy and treatment, median (range), mo	2.1 (0-244.5) 11 missing
Follow-up duration of all patients, median (range), y	5.9 (0-16.6)
Progression/death	69/30	26.4/11.5

CDOP, cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone; CHEP, cyclophosphamide, doxorubicin, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; DA-EPOCH, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; GCVP, gemcitabine, cyclophosphamide, vincristine, and prednisolone; IFN, interferon; R-CHOP, rituximab with CHOP.

^*Percentages pertain to patients with available data.

^†Brand (generic): Cytoxan (cyclophosphamide); Decadron (dexamethasone).